Dr Mark Lythgoe
@drmarklythgoe.bsky.social
Medical Oncology fellow & Pharmacist at @imperialcollege @ImperialSandC doing PhD in #cancer #microbiome -interest in health policy, drug development & @rovers
#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
December 29, 2024 at 2:49 PM
#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.
Will this be the preferred route of administration or will this suppress the development of new biosimilars?
@oncodaily.bsky.social @hemoncwarner.bsky.social